Emergent BioSolutions (EBS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Emergent BioSolutions (EBS) is Neutral.

The composite score behind that read is +0.06, weighing +0.19 of bullish evidence against -0.25 bearish.

Emergent BioSolutions last closed at $7.06, +3.67% on the session.

Against the IVW growth benchmark the position is +2.87% over the forecast window.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 53%.

12 graded predictions for EBS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Emergent BioSolutions in the 21st percentile on return on equity, where 100 is best.

Emergent BioSolutions is classified under Health Care / Biotechnology, with a market capitalisation of $349.17M.

StockMap tracks Emergent BioSolutions as the 204th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Emergent BioSolutions ranks 59th of 381 in the group, against a group median of -0.08.